Apolipoprotein B: A clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis

Journal of Internal Medicine

Volumn 258, Issue 5, 2005, Pages 395-410

  Olofsson, Sven Olof ^a   Boren, J ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Apolipoproteins B; Atherosclerosis; Proteoglycans; Very low density lipoprotein assembly; Very low density lipoproteins

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PROTEOGLYCAN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN 2;

AMINO ACID SEQUENCE; ARTERY INTIMA; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING AFFINITY; GOLGI COMPLEX; HUMAN; LIPID ANALYSIS; LIPOGENESIS; LIVER; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; SEQUENCE ANALYSIS;

APOLIPOPROTEIN B-100; APOLIPOPROTEIN B-48; APOLIPOPROTEINS B; ARTERIOSCLEROSIS; GLYCOSAMINOGLYCANS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, VLDL; MODELS, BIOLOGICAL; PROTEOGLYCANS; RISK FACTORS; TRIGLYCERIDES;

EID: 27544438601     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01556.x     Document Type: Review

References (116)

1. Karpe F. Postprandial lipoprotcin metabolism and atherosclerosis. J Intern Med 1999; 246: 341-55.
2. Taskinen MR. Diabetic dyslipidacmia: from basic research to clinical practice. Diabetologia 2003; 46: 733-49.
3. Segrest JP, Jones MK, De Loof H, Dashti N. Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 2001; 42: 1346-67.
4. Kim E, Young SG. Genetically modified mice for the study of apolipoprotein B. J Lipid Res 1998; 39: 703-23.
5. Stillemark-Billton P, Beck C, Boren J, Olofsson SO. Relation of the size and intracellular sorting of apoB to the formation of VLDL 1 and VLDL 2. J Lipid Res 2005; 46: 104-14.
6. Davidson NO, Shelness GS. Apolipoprotein B: mRNA editing. Hpoprotein assembly, and presecretory degradation. Annun Rev Nutr 2000; 20: 169-93.
7. Anant S, Davidson NO. Molecular mechanisms of apolipoprotein B mRNA editing. Curr Opin Lipidol 2001; 12: 159-65.
8. Wang AB, Liu DP, Liang CC. Regulation of human apolipoprotein B gene expression at multiple levels. Exp Cell Res 2003; 290: 1-12.
9. Dashti N, Gandhi M, Liu X et al. The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for Hpoprotein assembly, Biochemistry 2002; 41: 6978-87.
10. Chatterton JE, Phillips ML, Curtiss LK et al. Immunoelectron microscopy of low density lipoproteins yields a ribbon and bow model for the conformation of apolipoprotein B on the lipoprotein surface. J Lipid Res 1995; 36: 2027-37.
11. Boren J, Lee I, Zhu W et al. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J Clin Invest 1998; 101: 1084-93.
12. Boren J, Ekstrom U, Agren B et al. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem 2001; 276: 9214-8.
13. Olofsson S-O, Asp L, Borén J. The assembly and secretion of apolipoprotein B-containing lipoproteins. Curr Opin Lipidol 1999; 10: 341-6.
14. Olofsson S-O, Stillemark-Billton P, Asp L. The intracellular assembly of VLDL - a process that consists of two major steps that occur in separate cell compartments. Trends Cardiovasc Med 2000; 10: 338-45.
15. Gibbons GF, Wiggins D, Brown AM, Hebbachi AM. Synthesis and function of hepatic very-low-density lipoprotein. Biochem Soc Trans 2004; 32: 59-64.
16. Olofsson S-O, Asp L. The assembly of very low density lipoproteins (VLDL) in the liver. In: Packard CJ. Rader D. eds. Lipid and Atherosclerosis: Advances in Translational Medicine. London UK: Taylor and Francis. 2005: 1-15.
17. Johnson AE, van Waes MA. The translocon: a dynamic gateway at the ER membrane. Annu Rev Cell Dev Biol 1999; 15: 799-842.
18. Johnson AE, Haigh NG. The ER translocon and retrotranslocation: is the shift into reverse manual or automatic? Cell 2000; 102: 709-12.
19. Ellgaard L, Molinari M, Helenius A. Setting the standards: quality control in the secretory pathway. Science 1999; 286: 1882-8.
20. Lippincott-Schwartz J, Roberts TH, Hirschberg K. Secretory protein trafficking and organelle dynamics in living cells. Annu Rev Cell Dec Biol 2000; 16: 557-89.
21. Ellgaard L, Helenius A. ER quality control: towards an understanding at the molecular level. Curr Opin Cell Biol 2001; 13: 431-7.
22. Ellgaard L, Helenius A. Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 2003; 4: 181-91.
23. Kostova Z, Wolf DH. For whom the bell tolls: protein quality control of the endoplasmic reticulum and the ubiquitin-proteasome connection. EMBO J 2003; 22: 2309-17.
24. Elsner M, Hashimoto H, Nilsson T. Cisternal maturation and vesicle transport: join the band wagon (Review)! Mol Membr Biol 2003; 20: 221-9.
25. Kartberg F, Elsner M, Froderberg L et al. Commuting between Golgi cisternae-mind the GAP! Biochim Biophys Acta 2005; 1744: 351-63.
26. Borén J, Graham L, Wettesten M et al. The assembly and secretion of apoB 100-containing lipoproteins in Hep G2 cells. ApoB 100 is cotranslationally integrated into lipoproteins. J Biol Chem 1992; 267: 9858-67.
27. Boström K, Borén J, Wettesten M et al. Studies on the assembly of apo B-100-containing lipoproteins in HepG2 cells. J Biol Chem 1988; 263: 4434-42.
28. Gordon DA, Jamil H, Gregg RE et al. Inhibition of the microsomal triglyceride transfer protein blocks the first step of apolipoprotein B lipoprotein assembly but not the addition of bulk core lipids in the second step. J Biol Chem 1996; 271: 33047-53.
29. Rustaeus S, Stillemark P, Lindberg K et al. The microsomal triglyceride transfer protein catalyzes the post-translational assembly of apolipoprotein B-100 very low density lipoprotein in McA-RH7777 cells. J Biol Chem 1998; 273: 5196-203.
30. Stillemark P, Borén J, Andersson M et al. The assembly and secretion of apolipoprotein-B48-containing very low density lipoproteins in McA-RH7777 cells. J Biol Chem 2000; 275: 10506-13.
31. Sitia R, Braakman I. Quality control in the endoplasmic reticulum protein factory. Nature 2003; 426: 891-4.
32. Ahner A, Brodsky JL. Checkpoints in ER-associated degradation: excuse me, which way to the proteasome? Trends Cell Biol 2004; 14: 474-8.
33. Kleizen B, Braakman I. Protein folding and quality control in the endoplasmic reticulum. Curr Opin Cell Biol 2004; 16: 343-9.
34. Schroder M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem 2005; 74: 739-89.
35. Asp L, Claesson C, Borén J, Olofsson S-O. ADP-ribosylation factor 1 and its activation of phospholipase D are important for the assembly of very low density lipoproteins. J Biol Chem 2000; 275: 26285-92.
36. Asp L, Magnusson B, Rutberg M et al. Role of ADP ribosylation factor 1 in the assembly and secretion of ApoB-100-containing lipoproteins. Arterioscler Thromb Vasc Biol 2005; 25: 566-70.
37. 7 Adiels M, Packard C, Caslake MJ et al. A new combined multicompartmental model for apolipoprotein B-100 and triglyceride metabolism in VLDL subtractions. J Lipid Res 2005; 46: 58-67.
38. Wiggins D, Gibbons GF. The lipolysis/esteritication cycle of hepatic triacylglycerol. Its role in the secretion of very-low-density lipoprotein and its response to hormones and sulphonylureas. Biochem J 1992; 284: 457-62.
39. Salter AM, Wiggins D, Sessions VA, Gibbons GF. The intracellular triacylglycerol/fatty acid cycle: a comparison of its activity in hepatocytes which secrete exclusively apolipoprotein (apo) B100 very-low-density lipoprotein (VLDL) and in those which secrete predominantly apoB48 VLDL. Biochem J 1998; 332: 667-72.
40. Gibbons GF, Islam K, Pease RJ. Mobilisation of triacylglycerol stores. Biochim Biophys Acta 2000; 1483: 37-57.
41. Lehner R, Vance DE. Cloning and expression of a cDNA encoding a hepatic microsomal lipase that mobilizes stored triacylglycerol. Biochem J 1999; 343: 1-10.
42. Trickett JI, Patel DD, Knight BL et al. Characterization of the rodent genes for arylacetamide deacetylase. a putative microsomal lipase, and evidence for transcriptional regulation. J Biol Chem 2001; 276: 39522-32.
43. Gilham D, Ho S, Rasouli M et al. Inhibitors of hepatic microsomal triacylglycerol hydrolase decrease very low density lipoprotein secretion. FASEB J 2003; 17: 1685-7.
44. Dolinsky VW, Douglas DN, Lehner R, Vance DE. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem J 2004; 378: 967-74.
45. Dolinsky VW, Gilham D, Alam M et al. Triacylglycerol hydrolase: role in intracellular lipid metabolism. Cell Mol Life Sci 2004; 61: 1633-51.
46. Alexander CA, Hamilton RL, Havel RJ. Subeellular localization of B apoprotein of plasma lipoproteins in rat liver. J Cell Biol 1976; 69: 241-63.
47. Marchesan D, Rutberg M, Andersson L et al. A phospholipase D-dependent process forms lipid droplets containing caveolin, adipocyte differentiation- related protein, and vimentin in a cell-free system. J Biol Chem 2003; 278: 27293-300.
48. Boström P, Rutberg M, Ericsson J et al. Cytosolic lipid droplets increase in size by a microtubule dependent complexes formation. Arterioscler Thromb J Vasc Biol 2005; 25: 1945-51.
49. Ost A, Ortegren U, Gustavsson J et al. Triacylglycerol is synthesized in a specific subclass of caveolae in primary adipocytes. J Biol Chem 2005; 280: 5-8.
50. Olofsson S-O, Bjursell G, Boström K et al. Apolipoprotein B: structure, biosynthesis and role in the lipoprotein assembly process. Atherosclerosis 1987; 68: 1-17.
51. Murphy DJ, Vance J. Mechanisms of lipid-body formation. Trends Biochem Sci 1999; 24: 109-15.
52. Brown DA. Lipid droplets: proteins floating on a pool of fat. Curr Biol 2001; 11: R446-9.
53. Davidson NO, Shelness GS. Apolipoprotein B: mRNA ediling, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000; 20: 169-93.
54. Shelness GS, Sellers JA. Very-low-density lipoprotein assembly and secretion. Curr Opin Lipidol 2001; 12: 151-7.
55. Linden D, Lindberg K, Oscarsson J et al. Influence of agonists to the peroxisome proliferator activated receptor a (PPARa) on the intracellular turnover and secretion of apoB-100 and apoB-48. J Biol Chem 2002; 277: 23044-55.
56. Boström K, Wettesten M, Borén J et al. Pulse-chase studies of the synthesis and intracellular transport of apolipoprotein B-100 in Hep G2 cells. J Biol Chem 1986; 261: 13800-6.
57. Borén J, Rustaeus S, Wettesten M et al. Influence of triacylglycerol biosynthesis rate on the assembly of apoB-100-containing lipoproteins in HepG2 cells. Arterioscler Thromb 1993; 13: 1743-54.
58. Fisher EA, Pan M, Chen X et al. The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J Biol Chem 2001; 276: 27855-63.
59. Fisher EA, Ginsberg HN. Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem 2002; 277: 17377-80.
60. Mitchell DM, Zhou M, Pariyarath R et al. Apoprotein B 100 have a prolonged interaction with the translocon during which its lipidation and translocation change from dependence on the microsomal triglyceride transfer protein to independence. Proc Natl Acad Sci U S A 1998; 95: 14733-8.
61. Liang J-S, Wu X, Fisher EA, Ginsberg HN. The amino-terminal domain of apolipoprotein B does not undergo retrograde translocation from the endoplasmic reticulum to the cytosol. Proteasomal degradation of nascent apolipoprotein B begins at the carboxyl terminus of the protein, while apolipoprotein B is still in its original translocon. J Biol Chem 2000; 275: 32003-10.
62. Pariyarath R, Wang H, Aitchison JD et al. Co-translational interactions of apoprotein B with the ribosome and translocon during lipoprotein assembly or targeting to the proteasome. J Biol Chem 2001; 276: 541-50.
63. Williams KJ, Brocia RW, Fisher EA. The unstirred water layer as a site of control of apolipoprotein B secretion. J Biol Chem 1990; 265: 16741-4.
64. Horton JD, Shimano H, Hamilton RL et al. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmask hyperlipidemia resulting from production of lipid-rich VLDL. J Clin Invest 1999; 103: 1067-76.
65. Twisk J, Gillian-Daniel DL, Tebon A et al. The role of the LDL receptor in apolipoprotein B secretion. J Clin Invest 2000; 105: 521-32.
66. Gillian-Daniel DL, Bates PW, Tebon A, Attie AD. Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B. Proc Natl Acad Sci U S A 2002; 99: 4337-42.
67. Larsson SL, Skogsberg J, Bjorkegren J. The low density lipoprotein receptor prevents secretion of dense ApoB100-containing lipoproteins from the liver. J Biol Chem 2004; 279: 831-6.
68. Jiang XC, Li Z, Liu R et al. Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J Biol Chem 2005; 280: 18336-40.
69. Adeli K, Macri J, Mohammadi A et al. Apolipoprotein B is intracellularly associated with an ER-60 protease homologue in HepG2 cells. J Biol Chem 1997; 272: 22489-94.
70. Taghibiglou C, Rashid-Kolvear F. Van Iderstine SC et al. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase IB in a fructose-fed hamster model of insulin resistance. J Biol Chem 2002; 277: 793-803.
71. Adiels M, Boren J, Caslake MJ et al. Overproduction of VLDLI driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioseler Thromb Vasc Biol 2005; 25: 1697-703.
72. Malmström R, Packard CJ, Watson TD et al. Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioseler Thromb Vasc Biol 1997; 17: 1454-64.
73. Malmström R, Packard CJ, Caslake M et al. Effects of insulin and acipomox on VLDLI and VLDL2 apolipoprotein B in normal subjects. Diabetes 1998; 47: 779-87.
74. Malmstrom R, Packard CJ, Caslake M et al. Effect of heparin-stimulated plasma lipolytic activity on VLDL APO B subclass metabolism in normal subjects. Atherosclerosis 1999; 146: 381-90.
75. Berneis KK, Krauss RM. Metabolic origins and clinical signiticance of LDL heterogeneity. J Lipid Res 2002; 43: 1363-79.
76. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
77. Steinberg D, Parthasarathy S, Carew TE et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenidty. N Engl J Med 1989; 320: 915-24.
78. Vijayagopal P, Srinivasan SR, Radhakrishnamurthy B, Berenson GS. Interaction of serum lipoproteins and a proteoglycan from bovine aorta. J Biol Chem 1981; 256: 8234-41.
79. Iverius P-H. The interaction between human plasma lipoproteins and connective tissue glycosaminoglycans. J Biol Chem 1972; 247: 2607-13.
80. Camejo G, Lopez A, Vegas H, Paoli H. The participation of aortic proteins in the formation of complexes between low density lipoproteins and intima-media extracts. Atherosclerosis 1975; 21: 77-91.
81. Williams KJ, Tabas I. The response-to-retention hypothesis in early atherogenesis. Artheriosder Thromb Vasc Biol 1995; 15: 551-61.
82. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270.
83. Williams KJ, Tabas I. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 1928.
84. Srinivasan SR, Vijayagopal P, Dalferes ER Jr et al. Low density lipoprotein retention by aortic tissue. Contribution of extracellular matrix. Atherosclerosis 1986; 62: 201-8.
85. Schonherr E, Hausser H, Beavan L, Kresse H. Decorin-type I collagen interaction. Presence of separate core protein-binding domains. J Biol J Chem 1995; 270: 8877-83.
86. Camejo G, Eager G, Rosenberg B et al. Proteoglycans and lipoproteins in atherosclerosis. Curr Opin Lipidol 1993; 5: 385-91.
87. Pentikainen MO, Oorni K, Lassila R, Kovanen PT. The proteoglycan decorin links low density lipoproteins with collagen type I. J Biol Chem 1997; 272: 7633-8.
88. Kovanen PT, Pentikainen MO. Decorin links low-density lipoproteins (LDL) to collagen: a novel mechanism for retention of LDL in the atherosclerotic plaque. Trends Cardiovasc Med 1999; 9: 86-91.
89. Cardoso LE, Mourao PA. Glycosaminoglycan fractions from human arteries presenting diverse susceptibility to atherosclerosis have different binding affinities to plasma LDL. Arterioscler Thromb 1994; 14: 115-24.
90. Hurt-Camejo E, Olsson U, Wiklund O et al. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Arterioscler Thromb Vasc Biol 1997; 17: 1011-7.
91. Lindén T, Bondjers G, Camejo G et al. Affinity of LDL to a human arterial proteoglycan among male survivors of myocardial infarction. Eur J Clin Invest 1989; 19: 38-44.
92. O'Brien KD, Olin KL, Alpers CE et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 1998; 98: 519-27.
93. Borén J, Lee I, Zhu W et al. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apoB100. J Clin Invest 1998; 101: 1084-93.
94. Olsson U, Camejo G, Hurt-Camejo E et al. Possible functional interactions of apolipoprotein B-100 segments that associate with cell proteoglycans and the apoB/E receptor. Arterioscler Thromb Vasc Biol 1997; 17: 149-55.
95. Chan L. Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. J Biol Chem 1992; 267: 25621-4.
96. Skalen K, Gustafsson M, Rydberg EK et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750-4.
97. Ji ZS, Pitas RE, Mahley RW. Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than e4. J Biol Chem 1998; 273: 13452-60.
98. Pentikainen MO, Oorni K, Kovanen PT. Lipoprotein lipase (LPL) strongly links native and oxidized low density lipoprotein particles to decorin-coated collagen. Roles for both dimeric and monomeric forms of LPL. J Biol Chem 2000; 275: 5694-701.
99. Kugiyama K, Ota Y, Takazoe K et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999; 100: 1280-4.
100. Kleinman Y, Krul ES, Burnes M et al. Lipolysis of LDL with phospholipase A2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells. J Lipid Res 1988; 29: 729-43.
101. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E. Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 1999; 274: 25913-20.
102. Tabas I. Nonoxidative modifications of lipoproteins in atherogenesis. Annu Rev Nutr 1999; 19: 123-39.
103. Sniderman AD. How, when, and why to use apolipoprotein B in clinical practice. Am J Cardiol 2002; 90: 481-541.
104. Sniderman AD. Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. Curr Opin Lipidol 2004; 15: 433-8.
105. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004; 255: 188-205.
106. Walldius G, Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as targets for lipid-lowering therapy. Eur Heart J 2005; 26: 210-2.
107. Austin MA, Breslow JL, Hennekens CH et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 1988; 260: 1917-21.
108. Lamarche B, Tchernof A, Moorjani S et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95: 69-75.
109. Sniderman AD, Pedersen T, Kjekshus J. Putting low-density lipoproteins at center stage in atherogenesis. Am J Cardiol 1997; 79: 64-7.
110. Walldius G, Jungner I, Holme I et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
111. Walldius G, Jungner I, Aastveit AH et al. The apoB/apoA-1 ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004; 42: 1355-63.
112. Sacks FM, Alaupovic P, Moye LA et al. VLDL, apolipoproteins B. CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102: 1886-92.
113. Gotto AM Jr, Whitney E, Stein EA et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477-84.
114. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45.
115. Ameen C, Edvardsson U, Ljungberg A et al. Activation of peroxisome proliferator-activated receptor-α increases the expression and activity of microsomal triglyceride transfer protein in the liver. J Biol Chem 2005; 280: 1224-9.
116. Staels B, Dallongeville J, Auwerx J et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-93.